Isolation of Trypanosoma brucei gambiense from cured and relapsed sleeping sickness patients and adaptation to laboratory mice.
BACKGROUND: Sleeping sickness due to Trypanosoma brucei (T.b.) gambiense is still a major public health problem in some central African countries. Historically, relapse rates around 5% have been observed for treatment with melarsoprol, widely used to treat second stage patients. Later, relapse rates...
Saved in:
Main Authors: | Patient Pati Pyana (Author), Ipos Ngay Lukusa (Author), Dieudonné Mumba Ngoyi (Author), Nick Van Reet (Author), Marcel Kaiser (Author), Stomy Karhemere Bin Shamamba (Author), Philippe Büscher (Author) |
---|---|
Format: | Book |
Published: |
Public Library of Science (PLoS),
2011-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Melarsoprol sensitivity profile of Trypanosoma brucei gambiense isolates from cured and relapsed sleeping sickness patients from the Democratic Republic of the Congo.
by: Patient Pyana Pati, et al.
Published: (2014) -
Neural Damage in Experimental Trypanosoma brucei gambiense Infection: The Suprachiasmatic Nucleus
by: Chiara Tesoriero, et al.
Published: (2018) -
Sensitivity and specificity of HAT Sero-K-SeT, a rapid diagnostic test for serodiagnosis of sleeping sickness caused by Trypanosoma brucei gambiense: a case-control study
by: Dr. Philippe Büscher, PhD, et al.
Published: (2014) -
Aquaporin 2 mutations in Trypanosoma brucei gambiense field isolates correlate with decreased susceptibility to pentamidine and melarsoprol.
by: Fabrice E Graf, et al.
Published: (2013) -
Neopterin is a cerebrospinal fluid marker for treatment outcome evaluation in patients affected by Trypanosoma brucei gambiense sleeping sickness.
by: Natalia Tiberti, et al.
Published: (2013)